Little Response of Cerebral Metastasis from Hepatocellular Carcinoma to Any Treatments

Jung Ho Han, M.D., Dong Gyu Kim, M.D., Jong Cheol Park, M.D., Hyun-Tai Chung, M.D., Ph.D., Sun Ha Paek, M.D., Young Seob Chung, M.D., Ph.D.

Department of Neurosurgery, Seoul National University Bundang Hospital, Seongnam, Korea
Department of Neurosurgery, Seoul National University Hospital, Seoul, Korea
Department of Neurosurgery, Jeju University Hospital, Jeju, Korea
Department of Neurosurgery, Jeju National University Bundang Hospital, Jeju, Korea
Department of Neurosurgery, Seoul National University College of Medicine, Seoul, Korea

Objective: We retrospectively evaluated the survival outcome of patients with brain metastasis from hepatocellular carcinoma (HCC). The mean age of the patients was 54 ± 13 years, and 17 (85.0%) were men. Seventeen (85.0%) patients had already extracranial metastases. The median time from diagnosis of HCC to brain metastasis was 18.5 months. Fourteen (70.0%) patients had stroke-like presentation due to intracerebral hemorrhage (ICH). Ten (50.0%) patients had single or solitary brain metastasis. Among a total of 34 brain lesions, 31 (91.2%) lesions had hemorrhagic components.

Methods: Between 1991 and 2007, a total of 20 patients were diagnosed as having brain metastasis from HCC. The mean age of the patients was 54 ± 13 years, and 17 (85.0%) were men. Seventeen (85.0%) patients had already extracranial metastases. The median time from diagnosis of HCC to brain metastasis was 18.5 months. Fourteen (70.0%) patients had stroke-like presentation due to intracerebral hemorrhage (ICH). Ten (50.0%) patients had single or solitary brain metastasis. Among a total of 34 brain lesions, 31 (91.2%) lesions had hemorrhagic components.

Results: The median survival time was 8 weeks (95% CI, 5.08-10.92), and the actuarial survival rates were 85.0%, 45.0%, 22.5%, and 8.4% at 4, 12, 24, and 54 weeks. Age < 60 years, treatment of the primary and/or extracranial lesions, and recurrent ICH were the possible prognostic factors (p = 0.044, p < 0.001, and p = 0.111, respectively). The median progression-free survival (PFS) time was 3 months (95% CI, 0.95-5.05).

Conclusion: The overall survival of the patients with brain metastasis from HCC was very poor with median survival time being only 8 weeks. However, the younger patients less than 60 years and/or no extracranial metastases seem to be a positive prognostic factor.

KEY WORDS: Brain metastasis · Hepatocellular carcinoma · Survival outcome · Prognostic factor.

INTRODUCTION

Hepatocellular carcinoma (HCC) is a notorious cancer due to its aggressive clinical course and short survival time in Asian populations, and over the past two decades it has been a growing public health problem worldwide because its incidence has substantially increased. Therefore, HCC currently ranks as the fifth most common type of cancer in men worldwide, though it was formerly considered to be a rare disease in Western and European countries. In addition, recent therapeutic advances in surgical technique, transarterial chemoembolization (TACE), and various chemotherapeutic agents have contributed to the improved survival rate in these patients, which has increased the incidence of extrahepatic metastases.

However, even in the endemic areas, brain metastasis from HCC is so rare that the incidence was reported to be only about 0.2%. Only few exclusive studies reported that the prognosis is so poor when HCC spreads into the intracranial structures, including the skull and/or the brain, that the median survival time was just 1–2 months. Thus, the authors performed this retrospective study in an effort to identify both the overall survival time and the prognostic factors for patients with brain metastasis from HCC.

MATERIALS AND METHODS

Patients and inclusion criteria

Between 1991 and 2007, a total of 20 patients were diagnosed as having brain metastasis from HCC. In this study,
we included only the patients who had one or more brain parenchymal lesions with rim enhancement, homogeneous enhancement, or lobar hemorrhage suggesting neoplastic hemorrhage with enhancing solid portion (Fig. 1C) rather than hyperensive hemorrhage on brain computed tomography (CT) scan or magnetic resonance (MR) scan in the setting of histologically-confirmed HCC.

All patients underwent surgical resection or biopsy for the liver mass, and the histological confirmation of the HCC diagnosis was made in every case. All patients had had a history of liver cirrhosis after hepatitis B virus (HBV) infection in 17 (85.0%) patients, after HCV infection in 2 (10.0%), and after Clonorchis sinensis infection in one (5.0%). Brain lesion was histologically diagnosed as a metastasis from HCC in 7 (35.0%) patients, and the remaining 13 (65%) patients whose diagnosis of brain lesion was made only radiologically had the evidence of neoplastic hemorrhage with enhancing solid portion on MR images, suggesting a metastasis from HCC, and/or had multiple extracranial metastases in the lung, bone, and/or lymph nodes.

During the aforementioned period, a total of 41,400 patients were diagnosed as having HCC in our institute. Thus, the incidence of brain metastasis from HCC was 0.05%.

Data collection and treatments for brain metastasis

All patient data were based on information contained in hospital charts and radiological studies and were collected in accordance with the case record form approved by the institutional review board. Clinical data, including information on age, Child-Pugh classification, the level of alphafetoprotein (AFP), the Eastern Cooperative Oncology Group (ECOG) performance status, the RTOG recursive partitioning analysis (RPA) classification, radiological characteristics, treatment modality, and survival were collected. Any data that were missing from the medical records due to follow-up loss were obtained through a telephone interview with the patient or with his or her relatives, if deceased, after obtaining their permission.

The initial treatment modality and/or the adjuvant treatment for brain lesions was selected after our considering the patients' will and/or patients' status, such as presence of intracerebral hemorrhage (ICH) and its mass effect, possibility of surgical resection, and medical and functional condition of the patients. Conventional radiotherapy had been mainly selected as an initial or adjuvant treatment according to the physician's decision before 1998, when a Gamma Knife unit was installed in our institute.

Whole brain radiotherapy and/or Gamma Knife radiosurgery

Whole brain radiotherapy (WBRT) was initiated 1-2 weeks after surgery or diagnosis of brain metastasis with a total dose of 30-45 Gy and 3.0 Gy per fraction with five fractions per week. WBRT or Gamma Knife radiosurgery (GKS) was used only as an adjuvant treatment after failure of each modality.

GKS was performed using the Leksell Gamma Knife (Elekta Instrument AB, Stockholm, Sweden) model B or C. Treatment planning was performed using thin-sliced MR images. The radiosurgery isodose, maximum dose, and marginal dose were decided based on contrast-enhanced lesion volume, calculated during dose planning with the best-fit isodose method. Therefore, we prescribed about 20 Gy for small lesions less than 6 cm³ in volume, and reduced the dose gradually to 10 Gy according to increase of the lesion volume. The treatments were designed to deliver 45-70% of the maximum dose at the margins of the lesion.

Statistical analysis

The overall survival and prognostic factors were analyzed. Overall survival was defined as the interval between the date of diagnosis of brain metastasis and the date of death. The Kaplan-Meier method was used to estimate the overall survival distributions. A log-rank test was used to test for differences in overall survival between the groups according to a given covariate. All covariates were analyzed in the form of a categorical variable, such as age > 60 years, AFP >
400 ng/mL, ECOG performance status 3/4 or not, and RPA class 1/2 or not. The patients were also stratified into two groups according to whether or not surgical resection for brain metastasis was performed, and were stratified according to whether or not treatment for the primary and/or extracranial lesions was performed. To compare the distribution of the binomial variables, the Mann-Whitney U test were performed. All statistical analyses were performed at an α level of 0.05, using SPSS version 12.0 (SPSS Inc., Chicago, IL, USA).

RESULTS

Clinical and radiological features

The mean age of the patients was 55 ± 13 years (range, 22-76), and 17 (85.0%) were men. In 14 (70.0%) patients, brain metastasis was identified by work-up for neurological symptoms during follow-up of HCC. Metastasis to the lung and/or spine or para-aortic lymph nodes preceded brain metastasis in 10 patients, and metastasis only to the para-aortic lymph node and spine was identified before brain metastasis in each of two patients. In the remaining two patients, there was no evidence of extracranial metastases at the time of brain metastasis. In six (30.0%) patients, neurological symptoms were the first manifestation of HCC. The median time from diagnosis of HCC to brain metastasis was 18.5 months.

Five patients already had extracranial metastases discovered concurrently with development of neurological symptoms; four patients with lung and/or bone metastases and one with only bone metastasis. The rest one patient had no extracranial metastasis. Thus, overall 17 (85.0%) patients had already extracranial metastases. Only 3 (15.0%) had no evidence of extracranial metastasis after a thorough systemic work-up, and interestingly one female patient of them did not have any evidence of a viable tumor even in the liver and survived 165 weeks, the longest survival time of this series.

Presenting symptoms were hemiparesis and/or headache in 9 (45.0%) patients, visual field cut and headache in 5 (25.0%) patients, only headache in 3 (15.0%), and loss of consciousness in 3 (15.0%). Fourteen (70.0%) patients had stroke-like presentation due to ICH, and among them 12 patients were those whose brain metastases were identified during follow-up of HCC (p = 0.022).

At the time of brain metastasis, the severity of liver cirrhosis was classified as Child-Pugh grade A in 16 (80.0%) patients and B in the remaining 4 (20.0%) patients. None of the patients were classified as grade C, and no patient had a delayed prothrombin time. Among 18 patients whose serum AFP level was evaluated at the time of diagnosis of brain metastasis from HCC, the serum AFP level was within normal rage (0-20 ng/mL) in 6 (33.3%) patients.

Ten (50.0%) patients had single or solitary brain metastasis and the remaining half of the patients had multiple lesions up to three. Among a total of 34 brain lesions, 15 (44.1%) were located in the parieto-occipital area, 12 (35.3%) in the frontal lobe, 4 (11.8%) in the cerebellar hemisphere, and each one (2.9%) of the remaining three lesions in the temporal lobe, middle cerebellar peduncle, and the head of the caudate nucleus. The mean longest diameter of brain lesions defined as contrast-enhancing portion on MR images was 21 ± 13 mm (range, 4-50). The hemorrhagic components in or near the mass were radiologically identified in 31 (91.2%) lesions on the gradient echo MR images and/or CT scan (Fig. 1). The characteristics of the patients and the details of their management are summarized in Table 1.

Treatments

Seven (35.0%) patients underwent surgical resection of brain metastasis and/or ICH; three patients had complete resection and four patients had incomplete resection based on radiological findings after surgery; CT scan in three patients and MR imaging in four. The cause of incomplete resection in four patients was a profound bleeding from the metastatic lesions during surgery. Then, they were treated with WBRT in 6 patients and GKS in one patient. Among them, one patient underwent one cycle of chemotherapy using 5-fluorouracil and mitomycin (FM#1) for treatment of primary and/or extracranial lesions, and one had no evidence of disease after thorough systemic work-up at the time of brain metastasis.

Eleven (55.0%) patients were initially treated with radiation, such as GKS in 7 patients and WBRT in 4 patients. Among them, five patients underwent treatments for their primary and/or extracranial lesions; two patients were treated with one session of TACE, one with two sessions of TACE and FM#1, one with two cycles of chemotherapy using 5-fluorouracil, Adriamycin, and mitomycin, one with FM#4 and radiotherapy to the lung metastases (3,750 cGy in 15 fractions). The remaining two (10.0%) patients (patient No. 11 and 20) refused any treatments for their primary lesion and brain metastases.

Overall survival and progression free survival

As of January 2, 2008, a total of 18 (90.0%) patients died, and two (10.0%) were still alive with progressive disease in the brain parenchyma. In terms of the cause of death as determined using the protocol described by Patchell et al.17, there were 10 (50.0%) neurologic deaths and 8 (40.0%)
<table>
<thead>
<tr>
<th>Pt. No.</th>
<th>Sex</th>
<th>Age</th>
<th>Cause of LC</th>
<th>Time to metast (mo)</th>
<th>Presenting symptom</th>
<th>Location</th>
<th>Meta No.</th>
<th>ECOG</th>
<th>RPA class</th>
<th>Child-Pugh</th>
<th>Other meta</th>
<th>APP (ng/ml)</th>
<th>Presenting with ICH</th>
<th>Tx of brain meta</th>
<th>Tx of syst. Drs</th>
<th>Survival time (wk)</th>
<th>Cause of death</th>
<th>Recurrence</th>
<th>ICH</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>M</td>
<td>50</td>
<td>HBV</td>
<td>31</td>
<td>Visual D</td>
<td>PO</td>
<td>1</td>
<td>2</td>
<td>2</td>
<td>A</td>
<td>L</td>
<td>6</td>
<td>Yes</td>
<td>GMS/M2</td>
<td>FM/M/RTx (lung)</td>
<td>54</td>
<td>Systemic</td>
<td>No</td>
<td>0</td>
</tr>
<tr>
<td>2</td>
<td>F</td>
<td>46</td>
<td>HBV</td>
<td>21</td>
<td>Visual D</td>
<td>F/P/PO</td>
<td>3</td>
<td>3</td>
<td>2</td>
<td>A</td>
<td>L/B</td>
<td>15,100</td>
<td>No</td>
<td>WVRT/GKS</td>
<td>None</td>
<td>16</td>
<td>Neurologic</td>
<td>No</td>
<td>0</td>
</tr>
<tr>
<td>3</td>
<td>M</td>
<td>50</td>
<td>HBV</td>
<td>42</td>
<td>Visual D</td>
<td>PO</td>
<td>1</td>
<td>3</td>
<td>2</td>
<td>A</td>
<td>L</td>
<td>422,000</td>
<td>Yes</td>
<td>GKS</td>
<td>None</td>
<td>11</td>
<td>Neurologic</td>
<td>No</td>
<td>0</td>
</tr>
<tr>
<td>4</td>
<td>M</td>
<td>22</td>
<td>HBV</td>
<td>15</td>
<td>Visual D</td>
<td>PO</td>
<td>1</td>
<td>2</td>
<td>2</td>
<td>A</td>
<td>L/LN/S/P</td>
<td>450,000</td>
<td>Yes</td>
<td>GKS</td>
<td>FAM/M2</td>
<td>28</td>
<td>Systemic</td>
<td>No</td>
<td>0</td>
</tr>
<tr>
<td>5</td>
<td>M</td>
<td>65</td>
<td>HCV</td>
<td>20</td>
<td>Visual D</td>
<td>PO</td>
<td>1</td>
<td>2</td>
<td>2</td>
<td>A</td>
<td>L</td>
<td>64</td>
<td>Yes</td>
<td>STR/GKS</td>
<td>None</td>
<td>3</td>
<td>Neurologic</td>
<td>Yes</td>
<td>0</td>
</tr>
<tr>
<td>6</td>
<td>M</td>
<td>65</td>
<td>HCV</td>
<td>Concurrent</td>
<td>Hemiparesis</td>
<td>F/F</td>
<td>4</td>
<td>3</td>
<td>2</td>
<td>B</td>
<td>None</td>
<td>940</td>
<td>No</td>
<td>GKS</td>
<td>None</td>
<td>12</td>
<td>Neurologic</td>
<td>No</td>
<td>0</td>
</tr>
</tbody>
</table>

7 F 75 HBV Concurrent Hemiparesis Cbl 1 3 2 B L/B/LN 275 No GKS None 17 Systemic No
8 M 51 HBV Concurrent Hemiparesis F/P/O/PO 2 3 3 A L 1,700 No WVRT/GKS TACE#2/FM#1 29 Alive No
9 F 54 HBV Concurrent Hemiparesis F 1 3 1 B None <5 Yes GTR/WVRT NED 165 Systemic No
10 M 54 HBV Concurrent Hemiparesis PO/P/O/MCP 3 3 2 A L None <5 Yes STR/WVRT None 5 Neurologic Yes
11 M 65 HBV Concurrent Hemiparesis F 1 3 1 A L 16 Yes None None 4 Neurologic No
12 M 60 HBV Concurrent Hemiparesis F/P/O/Cbl 3 2 2 A L 3,200 Yes GKS None None 4 Systemic No
13 M 50 HBV Concurrent Hemiparesis F/P/F 3 3 3 A L 13,400 Yes STR/WVRT None 18 Neurologic Yes
14 M 68 HBV Concurrent Hemiparesis F/P/F 3 3 3 A L None <5 Yes STR/WVRT None 5 Neurologic No
15 M 52 HBV Concurrent Hemiparesis F/P/O 2 4 3 A B 13 Yes WVRT/GKS None 9 Systemic No
16 M 57 HBV Concurrent Hemiparesis F/P/O 2 4 3 A L 13,400 Yes STR/WVRT None 9 Neurologic No
17 M 52 HBV Concurrent Hemiparesis F/P/O/Cbl 3 2 2 A B None <5 Yes GTR/WVRT NED 16 Neurologic No
18 M 44 HBV Concurrent Hemiparesis Cbll 1 1 1 A L/B/LN 570 Yes GKS TACE#1 13 Alive Yes
19 M 76 HCV Concurrent Hemiparesis Cbl 2 2 2 A B None <5 Yes GMS/M2 No 16 Neurologic No


### Table 1. Characteristics of the patients and details of their management

- The median survival time was 8 weeks (95% CI, 5.0-10.92), and the actuarial survival rate was 81.0%, 43.5%, 22.5%, and 8.4% at 4, 12, 24, and 48 weeks.
- Seven (58%) of patients died without any follow-up imaging studies. Six patients died of hepatic failure, and the remaining one patient died due to hepatic encephalopathy.
- Among the 107 patients who received follow-up imaging studies, 80 (74.8%) did not show any significant change, while 27 (25.2%) showed significant regression, and 10 (9.3%) showed progression of the lesions on imaging studies. The overall frequency of any documented change on imaging studies was 13.5%, with an imaging change of any type in 15 patients (13.9%). The regression group was significantly younger than the other groups, with a median age of 56 years (range, 40-80) compared with 73 years (range, 21-86) in the non-regression group, and the progression group had a median age of 60 years (range, 40-85) compared with 73 years (range, 21-86) in the non-regression group.
- Neurological symptoms were the most frequent presenting symptom (89%), followed by gastrointestinal symptoms (31%), and respiratory symptoms (17%).
- Of the 107 patients who received follow-up imaging studies, 80 (74.8%) did not show any significant change, while 27 (25.2%) showed significant regression, and 10 (9.3%) showed progression of the lesions on imaging studies. The overall frequency of any documented change on imaging studies was 13.5%, with an imaging change of any type in 15 patients (13.9%). The regression group was significantly younger than the other groups, with a median age of 56 years (range, 40-80) compared with 73 years (range, 21-86) in the non-regression group, and the progression group had a median age of 60 years (range, 40-85) compared with 73 years (range, 21-86) in the non-regression group.
Fig. 2. Kaplan-Meier estimates of overall survival in the whole series (n = 20). The median survival time is 8 weeks (95% CI, 5.0-10.92), and the actuarial survival rates are 85.0%, 45.0%, 22.5%, and 8.4% at 4, 12, 24, and 54 weeks.

Fig. 3. Kaplan-Meier estimates to test for differences in overall survival between groups according to a given covariate using a log-rank test. A: The patients younger than 60 years show a longer median survival time than those older (18 weeks (95% CI, 6.87-29.13) vs. 12 weeks (95% CI, 4.30-19.70); p = 0.044). B: The patients whose primary and/or extracranial lesions were treated show a significantly longer median survival time than those without treatment for the primary and/or extracranial lesions (54 weeks (95% CI, 27.31-80.69) vs. 9 weeks (95% CI, 1.96-16.05); p < 0.001). "syst. Ds" in the figure means the primary and/or extracranial lesions. C: Patients with recurrent ICH after treatment show a poorer median survival time than those without it (5 weeks (95% CI, 0.23-9.86) vs. 16 weeks (95% CI, 10.56-21.44); p = 0.111).

Additional treatments and complications

Six (30.0%) patients had additional treatment for brain metastases; one patient underwent repeated radiosurgery for new lesions outside the initially treated lesion, four patients were treated with radiosurgery for progression of the brain metastasis or the new lesions outside the first brain lesion after WBRT, and the last one patient experienced surgery due to the recurrent ICH during WBRT after incomplete surgical resection.

No patients among 4 patients who underwent chemotherapy experienced hematologic toxicities assessed using World Health Organization common toxicity criteria version 2.0.

Six (30.0%) patients experienced recurrent ICH during follow-up period; four patients among them died or underwent repeat surgery due to recurrent ICH, and the remaining two patients were treated conservatively. The majority of recurrent ICHs developed within 2 weeks (4 days-8 weeks) after diagnosis of brain metastasis from HCC. Three (15.0%) patients experienced aggravation of edema around the brain lesion resulted in aggravation or development of hemiparesis after WBRT and/or GKS. Three (15.0%) patients experienced GI bleeding during the follow-up period.
and were treated with endoscopic esophageal varix ligation. And, each one of other three patients was treated due to hepatitis after herb medication, hepatic encephalopathy, and pneumonia, which were not directly related with treatments.

**DISCUSSION**

Though brain metastasis from HCC is a rare occurrence even in the endemic areas, it may become a major health problem in the near future due to the increasing incidence of HCC, especially in the western and European countries, and the prolonged survival due to the recent development of advanced therapeutic techniques. And, the incidence of brain metastases from HCC seems to be more than the previous estimations of 0.26% of the study of Chang et al., considering the report of 2.2% in Japanese autopsy series.

**Clinical and radiological features**

In the present study, overall 17 (85.0%) patients already had extracranial metastases to the lung, bone, and/or regional lymph nodes at the time of diagnosis of brain metastasis from HCC. Thus, brain metastasis from HCC seems to develop at the end stage of disease progression of HCC with dismal 5-year survival rate of less than 5 percent. Accordingly, the overall survival was very poor that the median survival time was only 8 weeks, and the actuarial survival rate was approximately 8% at one year. These findings may suggest that a more effective therapy for systemic HCC is required before any progress will be made with brain metastases.

Such a poor survival outcome may also result from some characteristic features of HCC brain metastasis. One of the noticeable features is that brain metastasis from HCC had a tendency of bleeding as in the previous reports, though no patients were classified as Child-Pugh grade C, and had a delayed prothrombin time in this study. Thus, 70.0% of the patients had stroke-like presentation due to tumor bleeding, and over 90% of the lesions had the hemorrhagic components in or near the mass on MR images and/or CT scan. In addition, six (42.9%) of 14 patients who had presented with overt ICH experienced recurrent bleeding from the tumors after treatments, which resulted in fatal outcomes in those patients. This high rate of ICH after treatments seemed to mainly result from the incomplete resection of the tumor in the patients who experienced surgical resection and also was partly caused by the insufficient liver function that alters the hemostasis. Furthermore, because the majority of the lesions were located near the sensory-motor cortex, complete surgical resection of the lesions were difficult and bleeding from the tumor had usually resulted in neurological deficits and functional decline of the patients, which made those patients not being eligible for further adjuvant treatments.

**Prognostic factors for overall survival**

Age less than 60 years and treatments for the primary and systemic extracranial metastases seems to be positively associated with overall survival of the patients with brain metastasis from HCC. This result may be in accordance with those of the studies dealing with patients with brain metastasis from other primary sites, such as lung, breast, kidney, colon, and so on; however, there may be some possible confounding variables in this result, such as the functional status of the patients and the state of the systemic disease, including the state of intrahepatic primary tumor and extracranial metastasis. Namely, treatments for the primary and systemic extracranial metastases might be possible only for the patients with relatively limited extent of disease and favorable general condition. Nevertheless, we did not perform the multivariate analysis to correct the possible confounding variables because its statistical power was expected to be low due to the small sample size.

One of the noticeable findings about brain metastasis from HCC is that it has a tendency of bleeding, and it can rebleed after treatment. In fact, recurrent bleeding from tumor itself is one of the possible prognostic factors found in this study, though it did not reach the statistical significance. However, it was most problematic event during management of patients with brain metastasis from HCC. In addition, the cause of 4 deaths among 10 neurological deaths was recurrent tumor bleeding (Table 1). Thus, recurrent tumor bleeding seems to be the only evident cause of neurologic death after treatment of brain metastasis from HCC.

Such a tendency of bleeding may be due to the pathological feature of brain metastasis of HCC of a trabecular or sinusoidal pattern and interspersed vascular channels. Considering that all four patients with incomplete surgical resection experienced recurrent ICH during or immediately after adjuvant WBRT, complete surgical resection should be obtained. If there are remnant tumors or unresectable lesions, GKS seems to be more useful than WBRT in terms of the time necessary for completion of each modality considering rapid progression of the neurological status and relatively early rebleeding from brain metastasis though it is obscure for GKS to prevent the recurrent bleeding and tumor progression rather than other modalities. However, one of the most important findings of this study is that decision of any treatments including surgical resection, WBRT, GKS, and chemotherapy should be cautiously made in
CONCLUSION

The overall survival of the patients with brain metastasis from HCC was very poor with median survival time being only 8 weeks, and the actuarial survival rate was approximately 8% at one year. Recurrent bleeding from tumor is one of the most problematic events in management of patients with brain metastasis from HCC. However, the younger patients less than 60 years and/or no extracranial metastases seem to be a positive prognostic factor.

Acknowledgements

This study was supported by Nuclear Research and Development Program of the Korea Science and Engineering Foundation (KOSEF) grant funded by the Korean Government (MEST) (Grant Code: M2010-0017604).

References